The European Medicines Agency says that no new patients should be started on Lilly Research Laboratories’s Lartruvo for soft tissue cancer after the product failed to meet the primary endpoint of overall survival in the Phase III ANNOUNCE trial.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?